TP53 and acute myeloid leukemia: Interestingly, TP53-mutated secondary AML and MDS are associated with the increased expression of programmed death ligand 1 (PD-L1), a major immune checkpoint molecule that leads to the anergy of effector T cells on hematopoietic stem cells and decreased numbers of cytotoxic/helper T cells in the bone marrow [108].